Sign In
Buy OGN
$13.40
+0.0200 (+0.149%)
At Close: Jun 03, 2026
Orogen Posts Profitable Financial Results and Cash Flow Strength in Q3-2025
07:30am, Tuesday, 25'th Nov 2025
VANCOUVER, BC / ACCESS Newswire / November 25, 2025 / (TSXV:OGN)(OTC:OGNNF) Orogen Royalties Inc. (formerly 1537944 BC Ltd.) ("Orogen" or the "Company") is pleased to announce robust profitability and
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
10:02am, Tuesday, 18'th Nov 2025
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
05:30am, Monday, 17'th Nov 2025
SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon and Henlius announce FDA approval of POHERDY, the first and only pertuzumab biosimilar in the US, which is interchangeable to Perjeta.
Kahn Brothers' Strategic Moves: GSK PLC Sees a -3.08% Impact
12:00pm, Wednesday, 12'th Nov 2025
Exploring Kahn Brothers (Trades, Portfolio)' Recent 13F Filing and Investment Strategies Kahn Brothers (Trades, Portfolio) recently submitted their 13F filing
Organon: Q3 Earnings Lift Struggling Stock - But Not For Long, I Suspect
12:58pm, Tuesday, 11'th Nov 2025
Organon & Co. faces ongoing challenges, with shares down over 75% since debut and recent CEO resignation after inventory probe. OGN Q3 results show stagnant revenues, declining Women's Health sales, a
Organon Analysts Cut Their Forecasts Following Q3 Results
11:40am, Tuesday, 11'th Nov 2025
Organon (NYSE:OGN) reported better-than-expected earnings for the third quarter on Monday.
Organon (OGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
02:36pm, Monday, 10'th Nov 2025
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Stre
Organon & Co. (OGN) Q3 2025 Earnings Call Transcript
10:51am, Monday, 10'th Nov 2025
Organon & Co. ( OGN ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Jennifer Halchak - Head of Investor Relations Carrie Cox Joseph Morrissey - Interim CEO & Executive VP an
Organon (OGN) Q3 Earnings and Revenues Beat Estimates
09:45am, Monday, 10'th Nov 2025
Organon (OGN) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.87 per share a year ago.
Organon Reports Results for the Third Quarter Ended September 30, 2025
07:30am, Monday, 10'th Nov 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025. “I am humbled to be working alongside our talented team during thi
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
07:30am, Friday, 07'th Nov 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon divests the JADA System for up to $465 Million to Laborie.
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
07:30am, Thursday, 06'th Nov 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to announce Q3 2025 financial results on November 10, 2025.
Orogen Announces Equity Compensation Grants
06:00pm, Wednesday, 05'th Nov 2025
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / November 5, 2025 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") announces the grant of 2,000,000 incentive Stock Options to
Nisa Investment Advisors LLC Has $214,000 Stake in Organon & Co. $OGN
03:55am, Tuesday, 04'th Nov 2025
Nisa Investment Advisors LLC trimmed its holdings in Organon and Co. (NYSE: OGN) by 48.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exc
Mutual of America Capital Management LLC Sells 4,109 Shares of Organon & Co. $OGN
05:04am, Thursday, 30'th Oct 2025
Mutual of America Capital Management LLC decreased its position in Organon and Co. (NYSE: OGN) by 11.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securi
